Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-BCMA With or Without huCART19 in High-Risk Multiple Myeloma
NCT03549442Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- May 2018
- Primary completion
- Mar 2036
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CART-BCMA and huCART-19 in multiple myeloma (MM) (4 arms), sponsored by University of Pennsylvania. Primary endpoint: Adverse event reporting at 90 Days. Started May 2018; status: active, not recruiting.
02
Drugs
CART-BCMAhuCART-19
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03549442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549442.